Center for Biologics Evaluation and Research (CBER)

February 27, 2012

The FDA successor to the Bureau of Biologics concerned with biologic drugs and with the new protein and peptide drugs arising from biotechnology. According to its charter, CBER is responsible for ensuring: • The safety of the U.S. entire blood supply and the products derived from it • The production and approval of safe and effective childhood vaccines, including any future AIDS vaccines • The proper oversight of human tissue for transplantation • An adequate and safe supply of allergenic materials and anti-toxins • The safety and efficacy of biological therapeutics, including an exciting new array of biotechnology-derived products used to treat diseases such as cancer and AIDS.
blog comments powered by Disqus
  • CRO-Sponsor Partnerships

    CRO-Sponsor Partnerships

    Craig Morgan, Brand Development Director, goBalto Inc.||October 11, 2016
    10 tips for enabling better CRO and sponsor collaborations

  • The Human Parts of Mouse Models

    The Human Parts of Mouse Models

    Julia Schueler, Head of in vivo Operations, Oncotest, a Charles River company ||October 11, 2016
    The PDX model system has come back into focus

  • The Search &  Rescue Mission for Data Integrity

    The Search & Rescue Mission for Data Integrity

    Mike Jovanis, Vice President of Vault QualityDocs, Veeva Systems||October 11, 2016
    Cloud technology is essential for success